Lu-177 PSMA Resistance and Next Steps for mCRPC
This article is for men with metastatic castration-resistant prostate cancer (mCRPC) who have received lutetium Lu-177 vipivotide tetraxetan (sometimes called Pluvicto) and whose cancer has continued to progress despite that treatment. If that is your situation, you are likely wondering what comes next. You are not out of options.
The VISION trial was a large phase III study that showed lutetium Lu-177 vipivotide tetraxetan significantly extended overall survival compared to standard of care in men with PSMA-positive mCRPC. Many men benefit from PSMA-targeted radioligand therapy, according to both clinical trials and real-world experience. But some men have limited response, and others progress after a period of control. When that happens, the treatment path needs to change, not stop.
This article walks through why resistance can occur, how your team identifies it, and what options may still be open to you.
What Are Your Next Steps When Lu-177 PSMA Is Not Working?
If your care team has confirmed that lutetium therapy is no longer controlling your cancer, these are the key questions to work through with your oncologist:
- Is this true progression, or could a PSA rise in the early weeks of treatment be a temporary flare?
- Have you had genetic testing for BRCA1, BRCA2, or other homologous recombination repair (HRR) gene mutations?
- If not yet received, is taxane chemotherapy like cabazitaxel now appropriate for your situation?
- Does your molecular profile support the use of a PARP inhibitor such as olaparib?
- Is your PSMA expression still high enough on repeat imaging to consider re-treatment or actinium-225 PSMA therapy?
- Are there open clinical trials in your region, or internationally, that may suit your case?
- Would a second opinion from a specialist nuclear medicine or prostate oncology center help clarify the best next step?
What Does 'Not Responding' Actually Mean?
Not every patient with mCRPC responds the same way to Lu-177 PSMA therapy. Some see a sustained PSA drop and stable scans. Others benefit for a period before the cancer begins to grow again. A smaller group sees little response from the start.
One important distinction: a short-term PSA rise in the first few weeks after treatment is not always a sign of failure. This pattern, sometimes called a PSA flare, happens in radioligand therapy. Your team will usually look for a confirmed upward trend across two or more measurements before concluding that true progression is occurring. This article on PSA flares after the first Lu-177 PSMA injection explains when a rising number is expected and when it is a genuine cause for concern.
True treatment resistance means the cancer is growing despite ongoing or completed therapy. Your oncologist will usually confirm this with a rising PSA trend and new or enlarging lesions on imaging, typically a PSMA-PET scan, CT, or bone scan. Worsening symptoms like returning bone pain can also be an early signal.
Why Does Resistance to Lu-177 PSMA Happen?
Prostate cancer is not a single disease. It can evolve, and in some patients it evolves in ways that reduce the effect of lutetium therapy.
The main mechanism involves PSMA expression. Lutetium therapy works by finding and binding to the PSMA protein on the surface of prostate cancer cells. If cancer cells reduce or lose that protein over time, the therapy has fewer targets to attach to. A repeat PSMA-PET scan after progression may show this as reduced uptake in some or all lesions.
Research on therapy resistance mechanisms in prostate cancer shows several pathways involved. These include changes in androgen receptor signaling, activation of bypass growth pathways, and in a smaller group of patients, a shift toward a form of the disease that no longer depends on the androgen receptor and can develop neuroendocrine features. This last pattern is less common but more difficult to treat.
Genetic factors can also affect response. An analysis of TP53 alterations in mCRPC patients treated with Lu-177 PSMA found that patients with TP53 loss-of-function mutations may have a weaker response to radioligand therapy. Knowing a patient's molecular profile can help predict response and, when resistance develops, help guide what comes next.
How Your Team Decides When to Change Course
Your oncologist will not usually act on a single PSA value alone. They will look at a pattern over time. The signals that suggest a change of treatment is needed include:
- A confirmed, sustained rise in PSA across two or more consecutive blood tests.
- New lesions or clear growth of existing lesions on imaging.
- Worsening bone pain that was previously improving or stable.
- Changes in blood counts such as falling hemoglobin or platelets, which suggest the disease is putting the bone marrow under increasing pressure.
The standard course of lutetium Lu-177 vipivotide tetraxetan is up to six cycles, typically spaced six weeks apart. Progression can become apparent during a course or weeks or months after all cycles are completed. The follow-up monitoring plan is as important as the treatment itself. For an overview of what is tracked after your cycles end, this guide to post-cycle monitoring and next-step care planning covers the key markers and imaging checkpoints in detail.
What Are the Main Treatment Options After Lu-177 PSMA Progression?
There is no single correct answer. The right option depends on which treatments you have already received, your molecular profile, your organ function, and your overall health. Your oncologist will weigh these factors together. Here are the main paths that are typically considered.
Taxane Chemotherapy
If you have not yet received cabazitaxel, a taxane chemotherapy used in mCRPC, this remains an established option after radioligand therapy. A review of systemic therapies for metastatic castration-resistant prostate cancer shows that taxane chemotherapy continues to play a role even in heavily pre-treated patients when organ function allows. If you have already received both docetaxel and cabazitaxel, re-treatment with cabazitaxel is occasionally discussed in selected patients who had a good initial response, though this is used less often and is not standard for all patients.
For a detailed look at how Lu-177 PSMA fits into the treatment sequence alongside taxane chemotherapy, this article comparing Lu-177 PSMA with taxane chemotherapy in mCRPC after hormone failure covers the key evidence and how doctors weigh the options.
PARP Inhibitors for HRR-Mutated Disease
A meaningful proportion of men with mCRPC carry mutations in DNA repair genes. BRCA1 and BRCA2 are the best known, but other genes in the homologous recombination repair (HRR) pathway can also be relevant.
PARP inhibitors are a class of targeted therapy that exploit these mutations. They disrupt cancer cells' ability to repair their own DNA damage. Olaparib and rucaparib have received FDA approval for selected patients with mCRPC who carry relevant gene alterations, though availability varies by country. If you have not yet had germline (inherited) or somatic (tumor) genetic testing, this is a strong reason to ask for it now. A result showing a BRCA or HRR mutation may open a treatment path that would otherwise not be available to you.
Androgen Receptor-Targeted Agents
Drugs that target androgen signaling, such as enzalutamide or abiraterone, may still have a role in some patients, particularly if a specific androgen receptor-targeted agent was not part of your earlier treatment. How much benefit remains depends heavily on your prior treatment history and the molecular features of your tumor. Your oncologist will advise based on your full treatment record.
Re-treatment With Lutetium Lu-177 Vipivotide Tetraxetan
In selected patients who responded well to a first course of Lu-177 PSMA and later progressed, your doctor may recommend a second course of treatment. This approach is still under active study, and clinical trials are evaluating who benefits most from re-treatment. Whether it is feasible depends significantly on PSMA expression. If a repeat PSMA-PET scan shows that the cancer cells still have meaningful PSMA protein on their surface, re-treatment may be an option. If PSMA expression has dropped significantly, a different approach is more appropriate. This article on retreatment eligibility after a first course of Lu-177 PSMA explains what the current evidence suggests about who may qualify.
Actinium-225 PSMA Therapy - An Emerging Option
Doctors are studying targeted alpha therapy using actinium-225 PSMA-617. Like lutetium therapy, it targets the PSMA protein on prostate cancer cells but delivers a different type of radiation called alpha particles. Alpha radiation is more potent over a very short range and might still work even when lutetium-based therapy has stopped working.
Research on PSMA-based and novel therapies in advanced prostate cancer identifies actinium-225 PSMA-617 as a promising next-line approach for patients who have progressed on lutetium therapy. Early studies show activity in this setting. Actinium-225 therapy is not yet widely approved, and access is limited to specialist centers, most of which offer it through clinical trials or compassionate access programs. Patients from countries where it is not available sometimes travel to access it, as many do for lutetium therapy itself.
Clinical Trials and Precision Oncology
The treatment landscape for mCRPC after radioligand therapy continues to evolve. Clinical trials are testing new combinations, including lutetium therapy paired with PARP inhibitors, immune checkpoint agents, and other targeted treatments, alongside entirely new approaches.
Research on PSMA-targeted radioligand therapy shows that combination strategies and earlier use of these therapies are key areas doctors are exploring to reduce or delay resistance.
If you want to search for open trials yourself, ClinicalTrials.gov is a public registry where you can look by condition (mCRPC), intervention (lutetium, PSMA, actinium), and sometimes by country. Your oncologist may also know of specialist trials not easy to find through general searches. Genomic testing from a blood-based liquid biopsy or fresh tissue biopsy can identify mutations that match specific trials or targeted agents. If your team hasn't tested your tumor recently, this is worth raising with them.
Getting a Second Opinion Before Deciding
Progression after Lu-177 PSMA is one moment in mCRPC where a second opinion from a specialist nuclear medicine or prostate oncology team can help. The field is moving quickly, and not every oncologist regularly sees patients at this stage of treatment. A specialist center may be aware of combination strategies, actinium-225 programs, or trials that are not yet routine in your current setting.
You can request a second opinion through Art of Healing Cancer on whether Lu-177 is right for you and what alternatives exist if not. The team there works with patients who have progressed through multiple lines of therapy and can help you understand what the evidence supports for your specific case, including options available in India and internationally.
Supporting Your Health During This Time
Hearing that a treatment has stopped working is difficult news to receive. Anxiety, disrupted sleep, and low mood are common responses, and they are not signs of weakness. Many patients find that addressing these symptoms alongside their medical plan helps them think more clearly during a period that involves complex, important decisions.
If sleep disruption or stress is making it harder to think through your options or rest between appointments, raise it with your care team. Some patients also look for over-the-counter options to use alongside their medical treatment during demanding periods. If you explore options like the Sleep and Stress range at Ayurnomics, which offers Ayurvedic formulations, discuss them with your doctor first.
When to Talk to Your Doctor
Contact your oncologist promptly if you notice any of the following after completing or during a course of Lu-177 PSMA therapy:
- A rising PSA on two or more consecutive blood tests.
- New or worsening bone pain.
- New symptoms that were not present before or during treatment.
- Fatigue or breathlessness that is getting worse rather than recovering over time.
- Any concern about changes that feel different from what your team described as expected.
You do not need to wait for a scheduled appointment if something feels wrong. Ask your team what monitoring is planned, when the next assessment is, and what your next options are for your situation.
If you want an independent specialist review before deciding on a next step, you can share your scans and treatment history with the team via the Lutetium Therapy contact form. If re-treatment or an alternative radioligand approach may be right for your case, the team will tell you. If it is not, they can help you understand what alternatives doctors recommend.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Can I still receive treatment if Lu-177 PSMA stops working?
Yes. Progressing after lutetium Lu-177 vipivotide tetraxetan does not mean all treatment options are gone. Depending on your treatment history, molecular profile, and overall health, next options may include cabazitaxel chemotherapy, PARP inhibitor drugs for patients with BRCA or HRR gene mutations, androgen receptor-targeted agents, re-treatment with lutetium therapy in selected patients, actinium-225 PSMA therapy, or clinical trials. Your oncologist will advise on which paths suit your specific situation.
How does my doctor know if Lu-177 PSMA therapy has stopped working?
Your team looks at more than one signal. A rising PSA trend across multiple blood tests, new or growing lesions on imaging - confirmed by PSMA-PET scan, CT, or bone scan - and worsening symptoms together suggest the cancer is no longer being controlled. A single PSA rise, especially in the early weeks of treatment, does not always confirm failure. Your oncologist will typically want to see a confirmed, sustained pattern before concluding that progression is occurring.
What is actinium-225 PSMA therapy and is it an option after Lu-177 fails?
Actinium-225 PSMA-617 is a targeted alpha therapy that works on the same PSMA-targeting principle as lutetium therapy but delivers a different, more potent type of radiation over a very short range. Pilot studies suggest it may be active in patients who have progressed on lutetium-based therapy. It is not yet widely approved and is currently available mainly through clinical trials or compassionate access programmes at specialist centres. Access varies considerably by country.
Does genetic testing matter after Lu-177 PSMA stops working?
Yes, it can make a significant difference. Patients with mutations in BRCA1, BRCA2, or other DNA repair genes may be eligible for PARP inhibitor drugs - targeted treatments not available to patients without these mutations. Genomic testing from a blood sample (liquid biopsy) or a tumour biopsy can also flag mutations that match open clinical trials. If your tumour has not been recently profiled, progression after radioligand therapy is a strong reason to ask your oncologist about testing.
Is a second course of Lu-177 PSMA ever possible after progression?
In selected patients who had a meaningful response to a first course and later progressed, re-treatment with lutetium Lu-177 vipivotide tetraxetan may be considered. Whether this is feasible depends largely on whether a repeat PSMA-PET scan still shows high PSMA expression on the cancer cells. If PSMA expression has dropped significantly, a different treatment approach is more appropriate. Re-treatment protocols are still being studied in clinical trials, and your nuclear medicine team can advise on your eligibility.
